Srini has over 18 years of investment and operational experience in the Life Sciences sector. He joined Sofinnova in 2013 as a General Partner, and concentrates on biopharmaceutical investments. Srini’s board memberships have included Piramed (acquired by Roche), Eyetech Pharmaceuticals (EYET), Synageva BioPharma (GEVA), Seattle Genetics (SGEN), Intercept Pharmaceuticals, (ICPT), and Versartis.
Prior to joining Sofinnova, Srini was a Managing Director at New Leaf Venture Partners. Prior to NLVP, he was a co-founder and Managing Director at Panorama Capital. Before forming Panorama, he served as Partner of JP Morgan Partners. Prior to JP Morgan Partners, Srini held business and corporate development positions at Genentech.
Srini MD and PhD degrees in Immunology from Stanford University School of Medicine. He graduated with BA degrees in both Biochemistry and Computer Science from Rice University.
Assistant: Tiffany Davis
Previous Board Seats
- Eyetech Public - (NASDAQ: EYET)
- Piramed Acquired Acquired - Roche
- Intercept Pharmaceuticals Public - (NASDAQ: ICPT)
- Seattle Genetics Public - (NASDAQ: SGEN)
- Synageva BioPharma Public - (NASDAQ: GEVA )